arrow
S

Sairah Ahmed

The University of Texas MD Anderson Cancer Center
H指数:46
被引数:8,721

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

免疫效应细胞相关神经毒性综合征的预测因素和结局:接受嵌合抗原受体T细胞治疗侵袭性B细胞非霍奇金淋巴瘤患者的分析

2026-10-210
PRE
Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma

纳武利尤单抗-AVD和 Brentuximab Vedotin-AVD在儿童和成人晚期霍奇金淋巴瘤中的真实世界结局

2026-09-290
PRE
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

EBV状态和组织学对纳武利尤单抗-AVD与博安拉塞-AVD在晚期经典霍奇金淋巴瘤中患者预后的影响(S1826)

2026-07-310
OA
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL

利萨库特根马拉鲁赛尔在3L+ FL中的持久疗效和可管理的长期安全性:TRANSCEND FL研究3年更新

Blood
IF23.1
2026-07-030
OA
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

SMART START试验的长期临床结果:利妥昔单抗、来那度胺和伊布替尼在 newly diagnosed large B-cell lymphoma 患者中的应用

2026-07-020
OAAI
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

中枢神经系统淋巴瘤患者中CD3xCD20双特异性抗体的临床疗效

2026-05-220
OAAI
Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma

造血细胞移植在浆细胞样淋巴瘤患者中的结局

2026-05-210
PRE
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

美国多中心回顾性研究:浆细胞样淋巴瘤的预后与治疗

2026-03-230
OAAI
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

利萨库肽马瑞卢赛尔在复发或难治性大B细胞淋巴瘤患者中的真实世界结局

Blood
IF23.1
2026-03-050
OA
Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-Analysis

完全缓解对复发或难治性大B细胞淋巴瘤患者长期生存的影响:一项CIBMTR前瞻性研究及SLR/Meta分析

2026-01-100
PRE
Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

青少年和年轻成人淋巴瘤幸存者心血管疾病诊断后的生存情况

2026-01-010
OAAI
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma

二线CD19 CAR-T治疗与铂类挽救疗法及自体干细胞移植治疗原发纵隔B细胞淋巴瘤的比较

2026-01-010
OA